ArticleJournal of inflammation research2025
Identification of Epigenetic Alteration of the IFI44L Gene in B Cells of Sjogren's Syndrome as a Clinical Biomarker and Molecular Significance.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Trends and Research Hotspots in Biomarkers of Sjögren's Syndrome Over the Past Two Decades: A Data-Driven Atlas Analysis.Immunity, inflammation and disease · 2026Review
- Epigenetic dysregulation of B‑cells in autoimmune diseases and lymphomas (Review).International journal of molecular medicine · 2026Review
- The Fibro-Immune Landscape Across Organs: A Single-Cell Comparative Study of Human Fibrotic Diseases.International journal of molecular sciences · 2026Article
- Multivariate analysis of glycogenes reveals coordinated regulation of immunoglobulin glycosylation in an immortalized human B cell system.bioRxiv : the preprint server for biology · 2025Article
- Keratoconjunctivitis Sicca in Sjögren Disease: Diagnostic Challenges and Therapeutic Advances.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Type 1 interferon (IFN-I)-related genes play a critical role in Sjögren's syndrome (SS). However, study on its role and impact in peripheral blood B cells of SS is limited. This study investigated gene expression and epigenetic changes in IFI44L, analyzing its correlation with disease activity and clinical indicators. Methods: Differentially expressed genes (DEGs) were identified from the GSE199868 dataset, while IFN-I-related genes were collected from GeneCards. Intersection analysis revealed IFN-I-related DEGs in SS. ClueGO, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, PPI network construction, and hub gene identification were conducted, with hub genes validated in GSE135809. Following this, we recruited 30 SS patients as the disease group and 11 healthy individuals as the control group. Clinical information and peripheral blood samples were collected from all participants. After isolating B cells from the peripheral blood, we used quantitative real-time polymerase chain reaction (RT-qPCR) and pyrosequencing to examine the mRNA expression and DNA methylation status of the IFI44L gene. Further analyses were conducted in conjunction with clinical indicators. Results: GSE199868 analysis revealed 125 upregulated and 16 downregulated DEGs. Among 2794 IFN-I-related genes from GeneCards, 26 DEGs overlapped, enriched in viral genome replication and IFN-I pathways. 14 hub genes were identified, with 7 genes confirmed in GSE135809: ISG15, IFIT1, OASL, IFI6, RSAD2, IFI44L, and USP18. IFI44L mRNA expression was significantly higher in SS B cells ( Conclusion: The study highlights the clinical relevance of IFI44L mRNA expression and DNA hypomethylation in SS, underscoring its potential as a biomarker for disease activity and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.